The phagocytosis of apoptotic cells (ACs), or efferocytosis, by DCs is critical for selftolerance and host defense. Although many efferocytosis-associated receptors have been described in vitro, the functionality of these receptors in vivo has not been explored in depth. Using a spleen efferocytosis assay and targeted genetic deletion in mice, we identified a multiprotein complex -composed of the receptor tyrosine kinase AXL, LDL receptorrelated protein-1 (LRP-1), and RAN-binding protein 9 (RANBP9) -that mediates DC efferocytosis and antigen cross-presentation. We found that AXL bound ACs, but required LRP-1 to trigger internalization, in murine CD8a + DCs and human-derived DCs. AXL and LRP-1 did not interact directly, but relied on RANBP9, which bound both AXL and LRP-1, to form the complex. In a coculture model of antigen presentation, the AXL/LRP-1/RANBP9 complex was used by DCs to cross-present AC-associated antigens to T cells. Furthermore, in a murine model of herpes simplex virus-1 infection, mice lacking DC-specific LRP-1, AXL, or RANBP9 had increased AC accumulation, defective viral antigen-specific CD8 + T cell activation, enhanced viral load, and decreased survival. The discovery of this multiprotein complex that mediates functionally important DC efferocytosis in vivo may have implications for future studies related to host defense and DC-based vaccines.
Introduction
Efferocytosis is the process by which apoptotic cells (ACs) are recognized and cleared by phagocytic cells (1, 2) . The crucial role of this process is exemplified by the development of spontaneous autoimmunity secondary to breakdown of self-tolerance in mice lacking certain efferocytosis receptors or their bridging molecules (3) (4) (5) (6) . Whereas macrophages are highly efficient at AC uptake (7) and are usually the focus of efferocytosis studies, efferocytosis by DCs can mediate the presentation of AC-associated antigens on MHC class I to naive and memory CD8 + T cells in a process called cross-presentation. This process has been proposed to induce either antigenic tolerance (8) or T cell priming against infectious agents (9) , depending on the specific context. Mostly in vitro studies have identified a number of distinct efferocytosis receptors that can be used by DCs (7, 10, 11) , suggestive of possible redundancy or tissue-or context-specific usage. However, the identity and mechanisms of receptors utilized by DCs to perform functionally important efferocytosis and cross-presentation in vivo constitutes a major gap in this important area of research.
Previous reports showed that the efferocytosis receptors CD36, αvβ5, and αvβ3 are not involved in antigen cross-presentation by DCs (12, 13) . Bone marrow-derived DCs (BMDCs) from the AXL/ TYRO3 double-KO mouse demonstrate defective efferocytosis in vitro (11) , but the role of AXL/TYRO3 in DC efferocytosis in vivo and in cross-presentation is not known. An important study showed that T cell Ig domain and mucin domain 3 (TIM-3) participates in AC uptake by DCs and cross-presents a model antigen OVA to OT-I transgenic T cells (10) . However, the relative contribution of TIM-3 in the context of other DC receptors and in functionally relevant cross-presentation is not known, especially because TIM-3 is also a negative regulator of T cell activation (14) . Recently, scavenger receptor class F, member 1 (SCARF-1), was reported to be important for efferocytosis by DCs, and SCARF-1-deficient mice developed a lupus-like autoimmune disease (15) . However, whether SCARF-1 plays a role in antigen cross-presentation or is utilized by human DCs was not explored. Given the critical role of DC efferocytosis and cross-presentation in maintaining tissue homeostasis, peripheral tolerance, and elicitation of antiviral immunity upon infection and vaccination, identification of the mechanisms and functionality of DC efferocytosis receptors in vivo is of paramount importance.
To address this critical gap in DC biology, we first used an in vivo spleen efferocytosis assay in which mice with absent or inhibited candidate DC efferocytosis receptors were injected with labeled ACs, followed by analysis of AC uptake by splenic DCs. Based on these initial findings, we carried out molecular-cellular studies and then gene-targeted mouse experiments to interrogate mechanism and function. This investigation led to the identification of a multiprotein efferocytosis complex that mediates DC efferocytosis in vivo. The proteins in the complex, AXL, LDL receptor-related protein-1 (LRP-1; also known as CD91), and RAN-binding protein 9 (RANBP9), were unable to effect efferocytosis on their own, but rather functionally interacted to coordinate AC binding and internalization. Most importantly, these molecules played a substantial, nonredundant role in the crosspresentation of AC-associated antigens in vivo, including in clearance of a viral infection. Human splenic and monocyte-derived DCs also used these molecules for efferocytosis. Knowledge of the presence and functionality of this multiprotein complex in DC efferocytosis may have implications for future studies related to host defense and DC-based vaccines.
Results

Splenic DCs utilize AXL, LRP-1, and TIM-3 for clearance of ACs in vivo and in vitro.
As a first approach to interrogating DC efferocytosis in vivo, we injected PKH67-labeled ACs into mice and then quantified the uptake of those ACs by splenic DCs using flow cytometry (16) . To help validate this assay, we took advantage of the fact that mature splenic DCs, which can be increased in mice by injection with the Toll-like receptor activator CpG-DOTAP, and CD8α -splenic DCs have low efferocytosis efficiency (7, 17) . The assay successfully identified DCs from CpG-treated mice and CD8α -DCs as poor efferocytes compared with DCs from untreated mice and CD8α + DCs, respectively ( Figure 1, A-C) . Furthermore, FACS sorting and confocal microscopic analysis of CD11c + PKH67 + splenocytes revealed that more than 97% of these cells showed evidence of AC internalization. A representative image demonstrating internalization of ACs in these sorted cells (CD11c + gate; Figure 1B ) is shown in Figure 1D . As an example of what noninternalization of ACs would look like by confocal microscopy, BMDCs were treated with the actin polymerization inhibitor cytochalasin D prior to addition of ACs. The z section sequence in this case showed that ACs were present only at the cell surface ( Figure 1D ). To further demonstrate internalization, we showed that efferocytosis in vivo was similar using either PKH67-labeled ACs or ACs labeled with the pH-sensitive dye Cypher-5E ( Figure 1E ), which fluoresces only after entering the acidic late endosomes or lysosomes.
Application of this assay to mice with absent or inhibited candidate receptors revealed that deficiency of CD36, CD11b, or MERTK did not affect efferocytosis by CD8α + splenic DCs (Figure 2A) . A previous study using BMDCs from AXL/TYRO3 double-KO mice demonstrated a role for one or both of these receptors in DC efferocytosis in vitro (11) . Here, we found that not only Axl -/-Tyro3 -/-mice, but also Axl -/-mice, were defective in DC efferocytosis in vivo (Figure 2A ), establishing that AXL is a physiologically important DC efferocytosis receptor.
We next explored LRP-1, which has previously been implicated in efferocytosis by macrophages, but not DCs (18, 19) . Inhibition of LRP-1 by i.v. injection of GST-conjugated receptor-associated protein (GST-RAP), which binds LRP-1 and inhibits interaction of the receptor with a number of LRP-1 ligands (Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI72051DS1; and ref. 20) , inhibited splenic DC efferocytosis by approximately 50% (Figure 2A ). To confirm the involvement of LRP-1 in DC efferocytosis, we generated Cd11cCre + Lrp1 fl/fl mice, which have undetectable LRP-1 in splenic DCs but intact expression in splenic macrophages (Supplemental Figure 1B) . CD8α + splenic DCs in these mice showed significantly decreased efferocytosis compared with control Lrp1 fl/fl mice ( Figure  2A ), further validating a role for LRP-1 in DC efferocytosis in vivo.
Further studies showed that CD8α + DCs, which had greater efferocytic efficiency than CD8α -DCs ( Figure 1C ), expressed substantially higher levels of AXL and LRP-1 compared with CD8α -DCs ( Figure 2 , D and E); this was also the case for another DC efferocytosis molecule, TIM-3 ( Figure 2F and see below). In this context, the decrease in efferocytosis observed in the Axl -/-and Cd11cCre + Lrp1 fl/fl mice was not due to changes in the number of total or CD8α + DCs (Figure 2 , B and C) or in the efferocytosis efficiency of splenic macrophages (Supplemental Figure 2) . Furthermore, the spatial distribution of DCs within the splenic marginal zone, where most of the injected ACs traffic (21), was not different among WT, Axl -/-, and Cd11cCre + Lrp1 fl/fl mice (data not shown).
We next explored 2 other molecules previously implicated in DC efferocytosis. Consistent with a previous report (10) , injection of anti-TIM-3 neutralizing antibody (nAb) decreased efferocytosis by DCs in vivo (Figure 2A ). An nAb against SCARF-1, another DC molecule recently shown to mediate the uptake of ACs (15) , also inhibited efferocytosis by BMDCs in vitro in a manner that was additive to AXL and TIM-3 (Supplemental Figure 3A ). Finally, we tested which molecules mediate efferocytosis by human splenic DCs and monocyte-derived DCs. Neutralization of AXL and LRP-1 using anti-AXL antibody and GST-RAP, respectively, was associated with a significant reduction in human DC efferocytosis ( Figure 3 , A and B). The degree of inhibition was comparable to that obtained by neutralization of CD36 and αvβ3/β5, which were previously reported to facilitate efferocytosis by human DCs (7). Importantly, simultaneous blockage of all the receptors resulted in an additive effect on efferocytosis inhibition ( Figure 3, A and B) . However, blocking SCARF-1 using an nAb did not decrease efferocytosis by human splenic DCs, either singly or in combination with other efferocytosis receptor blocking antibodies ( Figure 3B ). To demonstrate that the anti-SCARF-1 nAb was functional in human splenic DCs, we showed that it markedly decreased the uptake of one of SCARF-1's ligands, acetylated LDL (Ac-LDL; Supplemental Figure  3B ). Interestingly, AXL and LRP-1 were highly expressed on human CD141 + splenic DCs ( Figure 3C ), which are orthologous to murine CD8α + DCs in their efferocytosis and cross-presentation abilities (22, 23) . Thus, similar to our observations with AXL/LRP-1 and TIM-3 in mice, human monocyte-derived DCs and splenic DCs used AXL/LRP-1, but not SCARF-1, in conjunction with other, parallel receptor pathways to carry out efferocytosis.
AXL and LRP-1 cooperate to mediate efferocytosis. In view of our finding that the decreased DC efferocytosis in the spleens of Axl -/-, Cd11cCre + Lrp1 fl/fl , and TIM-3-neutralized mice was only partial, we next sought to determine whether DC efferocytosis can be blocked further by various combinations of receptor inhibition. When Axl -/-mice were treated with an anti-TIM-3 nAb, the inhibition of splenic DC efferocytosis was additive ( Figure 4A ). This was not the case for CD36 or αV integrins (Supplemental Figure 4A) , further supporting the data in Figure 2A suggesting these molecules are not involved in efferocytosis by murine DCs. Importantly, treatment of Axl -/-mice with the LRP-1 inhibitor GST-RAP did not result in any additional decrease in efferocytosis compared with each manipulation alone ( Figure 4B ), which suggests that LRP-1 and AXL function in the same pathway. In this context, it is important to note that expression levels of LRP-1 in Axl -/-DCs and AXL in LRP-1-deficient DCs were comparable to those in WT DCs (Supplemental Figure 4B) .
Figure 3
Human monocyte-derived DCs and splenic DCs utilize AXL and LRP-1 for efferocytosis. (A and B) Human monocyte-derived DCs (MoDCs; n = 5; A) and splenic DCs (n = 7; B) were incubated with IgG control or the indicated combinations of nAbs against AXL, CD36, αV, or SCARF-1 (0.5 μg/ml) (R&D Systems) or the LRP-1 blocker GST-RAP (1 μg/ml). Cells were then exposed to PKH67-labeled apoptotic Jurkat cells (1:4 ratio) for 2 hours and assayed for efferocytosis by microscopic analysis. (C) Representative flow cytometric analysis of expression levels of AXL and LRP-1 in human CD141 -and CD141 + splenic DCs (n = 5). *P < 0.05 vs. respective control; # P < 0.05 vs. all other groups (except as indicated).
To further explore the concept that AXL and LRP-1 might function in the same pathway, we considered the possibility that LRP-1 and AXL might carry out different steps in efferocytosis, such as AC recognition versus engulfment (24) . To assess the role of AXL and LRP-1 in AC binding, we used the actin polymerization inhibitor cytochalasin D to prevent AC internalization. Whereas Axl -/-DCs were clearly deficient in AC binding using this assay, inhibiting LRP-1 using GST-RAP did not affect this process (Figure 4C ). In contrast, when the assay was carried out in the absence of cytochalasin D to enable engulfment, both AXL deficiency and GST-RAP were inhibitory ( Figure 4D ). Similar results were obtained when the binding experiment was conducted at 4°C to block internalization (data not shown). Notably, blocking LRP-1 in Axl -/-BMDCs did not further augment the defect in AC engulfment ( Figure 4D ), consistent with the in vivo data in Figure 4B . These findings suggest a model in which AXL is involved primarily in AC recognition by DCs, whereas LRP-1 functions in engulfment of the bound ACs, but not AC binding per se.
RANBP9 facilitates the functional interaction of AXL and LRP-1 in efferocytosis.
We reasoned that if AXL and LRP-1 functioned in a binding-internalization cooperative manner, they might be in close proximity or even physically interact with each other. To test this hypothesis, we first conducted double immunofluorescence confocal microscopy on BMDCs. Within the resolution of this technique, the images were suggestive of AXL/LRP-1 colocalization on the cell surface ( Figure 5A ). We also found that LRP-1 was expressed at a higher level than AXL in DCs (data not shown), which likely explains our finding that percent colocalization of AXL with LRP-1 was higher than that of LRP-1 with AXL (78% vs. 41%). To test our hypothesis using a complementary method, we determined whether AXL and LRP-1 could be coimmunoprecipitated in BMDCs. co-IP experiments showed the presence of LRP-1 in AXL IPs and the presence of AXL in LRP-1 IPs ( Figure   5B ). Notably, AXL was not detected in the IPs of LRP-1 in Axl -/-DCs (Supplemental Figure 5A ), confirming the specificity of the antibodies used in these experiments. To determine whether AXL and LRP-1 interact in splenic DCs in vivo, we conducted a fluorescence resonance energy transfer (FRET) experiment in which primary antibodies recognizing AXL and LRP-1 were conjugated to Alexa Fluor 546 or Alexa Fluor 647 to act as FRET donor and acceptor, respectively. This assay was based on the principle that photons emitted by donor fluorophore can excite acceptor fluorophore when they are within 100Å of each other. A positive FRET is indicated by both an increase in fluorescence of the acceptor (sensitized emission) and a concomitant decrease in fluorescence of the donor (donor fluorescence quenching). FACS analysis of splenic DCs showed substantial FRET, as measured by analysis of both sensitized emission and donor fluorescence quenching ( Figure 5 , C and D). Moreover, consistent with our confocal data demonstrating greater colocalization of AXL with LRP-1, donor fluorescence quenching was greater when antibody against AXL was used as a donor ( Figure 5D ). As a control for this experiment, we showed that FRET was not observed in Axl -/-and LRP-1-deficient splenic DCs (Supplemental Figure 5B) , thereby validating the fluorophore-conjugated antibodies used in this assay. In addition, FRET between fluorophore-conjugated antibodies against heavy and light chains of MHC class I, which are known to interact on the cell surface, was used as a positive control (Supplemental Figure 5C) .
In order to determine the functional significance of AXL/LRP-1 interaction, it was necessary to identify the mechanism responsible for their association. Protein interaction algorithms suggested that LRP-1 and AXL do not directly bind each other, so we hypothesized the presence of a scaffolding protein. Further database searching indicated that the protein RANBP9 interacts with AXL in cancer cells (25) and with LRP-1 in neuronal cells (26) . Although RANBP9 has not previously been implicated in any functional interaction between AXL and LRP-1 or in efferocytosis, we considered the hypothesis that it can act as an AXL/LRP-1 scaffolding protein in DCs to couple AXL-mediated AC binding with LRP-1-mediated AC internalization.
We first probed the LRP-1 and AXL IPs for RANBP9 and found a positive immunoblot signal in both cases ( Figure 5B), consistent with our scaffolding hypothesis. To test the functional significance of this interaction, we created bone marrow chimeric mice using Ranbp9 -/-donor cells, because Ranbp9 -/-mice die in the early postnatal period (27) . Thus, fetal liver cells from E15 Ranbp9 -/-and WT embryos were transplanted into lethally irradiated C57BL/6J mice to generate chimeric mice in which BMDCs were deficient in RANBP9. As confirmation, we verified that splenic DCs in the In vivo splenic DC efferocytosis was assayed in the indicated mice (n = 3 per group) 3 hours after injection of PKH67-labeled ACs. TIM-3 nAb (100 μg) was administered i.p., and GST-RAP (2 mg/mouse) was administered i.v., 30 minutes before AC injection. (C) BMDCs derived from WT or Axl -/-mice were treated with 5 μg/ml cytochalasin D to block AC internalization. To measure AC binding, cells were incubated with fluorescently labeled ACs for 1 hour in the absence or presence of 1 μg/ml GST-RAP to block LRP-1. (D) Similar to C, except the experiment was conducted in the absence of cytochalasin D to measure AC engulfment. n = 3 independent experiments. *P < 0.05 vs. respective control; # P < 0.05 vs. all other groups. chimeric mice lost expression of RANBP9 compared with WT DCs (Supplemental Figure 6A) . However, neither the expression level of AXL and LRP-1 in DCs nor the total number of CD8α + DCs was affected by RANBP9 deficiency (Supplemental Figure 6 , B-D). Consistent with our hypothesis, RANBP9 deficiency in DCs (assessed using BMDCs from Ranbp9 fl/fl mice transduced with adeno-Cre) resulted in loss of FRET signal between AXL and LRP-1 ( Figure 6A ). Moreover, AXL failed to coimmunoprecipitate with LRP-1 in Ranbp9 -/-DCs ( Figure 6B ). These data demonstrated that RANBP9 deficiency disrupted AXL/LRP-1 interaction. Most importantly, efferocytosis by splenic DCs was defective in Ranbp9 -/-chimeric mice ( Figure 6C ), but efferocytosis by splenic macrophages was unaffected (Supplemental Figure 6E) . Furthermore, consistent with the concept that AXL functions to bind ACs, while AXL/LRP-1 interaction is necessary for subsequent engulfment, BMDCs from Ranbp9 -/-chimeric mice showed normal AC binding, but defective AC engulfment ( Figure 6D ). AC internalization after recognition by specific efferocytosis receptors involves actin cytoskeletal reorganization mediated by the GTP-bound form of Rac1 (28) . Previous reports indicated that LRP-1 mediates AC engulfment through its adapter protein, engulfment adaptor PTB domain containing 1 (GULP1) (29) , which facilitates the formation of Rac-GTP (30) . Consistent with our hypothesis that LRP-1/GULP1 is primarily involved in engulfment of AXL-bound ACs, silencing GULP1 using siRNA in WT BMDCs (knockdown efficiency, >80%; data not shown) led to a significant decrease in AC engulfment, but AC binding was unaffected ( Figure 6E ). Furthermore, silencing GULP1 in Axl -/-BMDCs did not result in an additional decrease in AC engulfment compared with Axl -/-BMDCs transfected with negative control scrambled RNA (Supplemental Figure 7) , which suggests that LRP-1/GULP1 by itself is unable to mediate AC recognition and internalization. These data support the concept that AXL and LRP-1/GULP1 function as a complex in which AXL binds ACs and LRP-1/GULP1 mediates AC engulfment through actin cytoskeletal rearrangement.
AXL-and LRP-1-deficient DCs do not have defects in macropinocytosis and phagocytosis. As a test of specificity for the role of the AXL/ LRP-1/RANBP9 complex in DC efferocytosis, we next determined whether these molecules also play roles in the related processes of macropinocytosis, endocytosis, and phagocytosis. BMDCs obtained from WT, Axl -/-, and Cd11cCre + Lrp1 fl/fl mice did not demonstrate any difference in the uptake of FITC-labeled dextran, a measure of macropinocytosis ( Figure 7A ). There was also no difference in the uptake of DiI-labeled LDL, a measure of receptor-mediated endocytosis ( Figure 7B ). Similarly, there was no difference in the ability of these DCs to phagocytose fluorescently labeled 1-μm latex beads ( Figure 7C ). Thus, AXL-and LRP-1-deficient DCs have a specific defect in efferocytosis.
The AXL/LRP-1/RANBP9 efferocytosis receptor complex is critical for cross-presentation of AC-derived antigens, both in vitro and in vivo. As mentioned above, one of the functional implications of DC efferocytosis is its ability to utilize AC-derived antigens for cross-presentation. We therefore tested whether ACs internalized via the AXL/LRP-1/ RANBP9 complex could provide antigens for cross-presentation. We first used an in vitro model in which DCs from WT, Axl -/-, or The OVA assays were conducted in vitro using a model antigen, which is not directly relevant in vivo under physiologic or pathologic conditions. We therefore tested whether efferocytosis via the AXL/ LRP-1/RANBP9 complex has relevance in antigen cross-presentation in a natural virus infection model. To achieve this, we used an experimental model of systemic herpes simplex virus-1 (HSV-1) infection in mice, because clearance of HSV-1 in vivo is dependent on successful cross-presentation and elicitation of a protective CD8 + T cell response (31) . To monitor cross-presentation and activation of antigen-specific CD8 + T cells, we used mice that were adoptively transferred with CFSElabeled CD8 + T cells isolated from gBT-I.1 transgenic mice. These T cells are MHC class I-restricted, with antigen specificity to the immunodominant peptide from HSV glycoprotein B (gB498-505) (32) . Mice lacking AXL, LRP-1 in DCs (Cd11cCre + Lrp1 fl/fl ), or RANBP9 in BMDCs had a significant increase in the number of nonproliferating gB498-505-specific CD8 + T cells in HSV-1-infected spleens ( Figure 9A and Supplemental Figure 8A ). Most importantly, in light of the role of CD8 + T cells in anti-HSV-1 immunity, all 3 KO models showed enhanced virus-induced pathogenesis, as demonstrated by adrenomegaly (Supplemental Figure 8B ), massive adrenal infiltration of monocytes and neutrophils (data not shown), and viral titers more than 3-fold higher than in control mice ( Figure 9B) . Moreover, the adrenal glands of the mutant mice showed a significant increase in the number of TUNEL + cells ( Figure 9C ), consistent with both increased HSV-1-induced apoptosis (33) and decreased efferocytic clearance of ACs. In theory, these data could be influenced by increased permissiveness of the KO cells to HSV-1 infection; however, HSV-1 infectivity was not increased in BMDCs lacking AXL or LRP-1 or in primary adrenal cells lacking AXL (Supplemental Figure 9) . Furthermore, to directly relate these data to efferocytosis of HSV-1-killed cells, we rendered primary adrenal cells apoptotic by ex vivo infection with HSV-1 and then injected these ACs into WT and mutant mice. Consistent with the interpretation of the HSV-1 infection data, Axl -/-and Cd11cCre + Lrp1 fl/fl mice demonstrated defective DC efferocytosis and decreased cross-presentation to gBT-I.1 CD8 + T cells (Supplemental Figure 10, A and B) . Finally, to confirm and extend the biological significance of these findings, we compared the survival of WT and Cd11cCre + Lrp1 fl/fl mice infected with a lethal dose of HSV-1 and found significantly decreased median survival in Cd11cCre + Lrp1 fl/fl compared with WT mice (Cd11cCre + Lrp1 fl/fl , 5.5 days; WT, 8.5 days; Figure 9D ). Thus, despite the presence of multiple DC efferocytosis receptors, the AXL/LRP-1/RANBP9 efferocytosis complex was functionally important in antigen acquisition for cross-presentation and elicitation of a protective CD8 + cytotoxic T cell response in the setting of a natural virus infection.
A recent in vitro study demonstrated that enveloped viruses utilize DC TYRO3/AXL/MERTK (TAM) family receptors, including AXL, to promote viral replication via suppression of type I IFN responses (34) . However, our in vivo data demonstrated that Axl -/-mice were more susceptible to HSV-1 (an enveloped virus) compared with WT mice on days 4, 7, and 10 after infection ( Figure 9B and Supplemental Figure 11A) . Moreover, the levels of IFN-α in serum were not significantly different between WT and Axl -/-mice (Supplemental Figure 11B) . These data raise the interesting possibility that the pathogen and host may compete for the same cellular machinery. For example, during initial phases of infection, viruses may utilize TAM receptors on DCs to suppress an early IFN-α response and promote viral replication, while during later stages of infection, particularly when virus-induced ACs arise, DCs utilize the TAM receptor AXL to recognize ACs, including virus-infected ACs, triggering activation of CD8 + cytotoxic T cell response and clearance of virus.
Discussion
Efferocytosis by DCs serves several important functions, including maintenance of tolerance to self-antigens; initiation of immune response against virally infected cells; and, in theory, prevention of secondary necrosis of uncleared ACs (8) . Numerous receptors have been implicated through in vitro and occasionally in vivo studies as being able to mediate AC uptake by a variety of phagocytic cell types (35) . While these studies suggest that different types of phagocytes preferentially utilize specific sets of receptors to carry out efferocytosis, there has been considerable uncertainty as to the receptors used by DCs for functionally important efferocytosis in vivo. The findings of the present study help clarify this critical area, with implications for understanding the roles of DC efferocytosis in physiology, pathophysiology, and possibly therapy, such as in DC-vaccine design (36) .
AXL interacts with ACs through the bridging molecule GAS6, which binds both AXL and phosphatidylserine exposed on the surface of ACs (37) . However, the mechanism by which AXL mediates AC engulfment was not previously elucidated. Here, we demonstrated that in murine DCs, AXL primarily acted as an AC recognition receptor that bound ACs, but did not internalize them. Engulfment of the bound ACs required RANBP9-mediated interaction of AXL with the LRP-1/GULP1 module. This mode of action raises the possibility of the tether-and-tickle hypothesis proposed by Henson and colleagues, in which macrophages were shown to bind ACs through one of a number of receptors, but internalization required another molecule, referred to as PSR (24) . In DCs, AXL is an AC tether, and it is possible that this process somehow "tickles" the LRP-1/GULP complex to mediate cytoskeletal rearrangement and AC internalization. However, further studies will be needed to define if and how AC binding trig- Efferocytosis prevents secondary necrosis of ACs, and defects in efferocytosis have been linked to pathological tissue necrosis, such as that in the necrotic cores of advanced, clinically dangerous atherosclerotic lesions (47) . For example, deletion of the macrophage efferocytosis receptors MERTK and LRP-1 have been demonstrated to exacerbate necrotic core formation in mouse models of advanced atherosclerosis (19, 48, 49) . Interestingly, observational studies have shown that the necrotic cores of clinically dangerous human atheromata are often surrounded by mature DCs, which are relatively inefficient efferocytes that can constitute up to 30% of the phagocyte population of atherosclerotic lesions (7, 50, 51) . Thus, pathologic accumulation of pools of efferocytosis-inefficient mature DCs may promote focal necrosis. However, testing of this hypothesis in atherosclerosis and in other pathological settings, such as in tumor immunosurveillance, has been hampered by lack of knowledge of DC-specific efferocytosis receptors (2, 52) . Here, we found that neither TIM-3 neutralization nor RANBP9 deficiency blocked efferocytosis by macrophages in vivo (Figure 2 and Supplemental Figure 6E) ; thus, targeting these molecules may provide a strategy by which to interrogate the role of DC-specific efferocytosis in these settings. Moreover, given the critical role of efferocytosis and antigen cross-presentation in suppressing autoimmune responses, future investigation of the role of the AXL/LRP-1/RANBP9 complex in this area is warranted.
In summary, we characterized a new multiprotein complex utilized by DCs for efferocytosis and antigen cross-presentation in vivo and demonstrated a novel role for the scaffolding protein RANBP9 in facilitating DC efferocytosis. In addition to providing new insight and tools with which to study the physiologic and pathologic roles of DC efferocytosis, these findings may have implications for future DC-based immunotherapeutic strategies. For example, proteins or peptides packaged in AC-mimetic nanoparticles targeted to the AXL/LRP-1/RANBP9 complex may enhance efficiency of antigen cross-presentation for the purpose of eliciting a desired immune response against cancer or pathogens or a tolerogenic response in the setting of autoimmunity.
Methods
Animals and animal maintenance. Cd11b -/-and OT-1 mice were obtained from Jackson Laboratories (stock nos. 003991 and 003831, respectively). Axl -/-Tyro3 -/-, Axl -/-, and Mertk -/-mice were generated as described previously (53, 54) . Lrp1 fl/fl mice (strain name B6;129S7-Lrp1tm2Her/J; JAX stock no. 012604) were generated as described previously (55) and then bred with Cd11cCre +/+ mice (Jackson Laboratories; stock no. 008068) to generate Cd11cCre + Lrp1 fl/fl mice. Ranbp9 -/-embryos were harvested from pregnant mice obtained from Ranbp9 +/-mating (27) . Ranbp9 fl/fl mice, with exon 3 flanked by loxP sites, were generated using a targeting vector consisting of an FRT site-flanked β-neo cassette with loxP sites inserted upstream and downstream of exon 3 of the Ranbp9 gene. This construct was electrophoresed into JM8A3 F1-derived ES cells. An ES cell clone (HEPD0592.3.D06) that had successfully undergone FLP-mediated recombination and no longer retained the cassette, but did retain the loxP-flanked exon 3, was obtained from The European Conditional Mouse Mutagenesis Program and injected in to C57BL/6 blastocysts. Male chimeric mice were then bred to C57BL/6J female mice for germline transmission. Male and female heterozygous Ranbp9 fl/+ mice were bred with each other to generate homozygous Ranbp9 fl/fl mice, which were used as a source of BMDCs for this study. gBT-I.1 mice were provided by D. Carr (University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA).
gers activation of the LRP-1/GULP complex, including whether RANBP9 simply keeps AXL and LRP-1 close enough to allow a direct tickle-type interaction between AXL and LRP-1 or whether RANBP9 plays a more complex role in the actual transmission of the putative tickle signal.
Several lines of in vitro evidence suggest that antigens derived from ACs via efferocytosis are cross-presented by DCs to activate antigen-specific CD8 + T cells (9, 38, 39) . Antigen cross-presentation is an incompletely understood process that involves transfer of antigen-derived peptides into the cytosolic or vacuolar pathway for loading onto MHC class I (40) . This process is influenced by a number of factors, including efficiency of antigen capture, nature of antigen, dose, expression levels of MHC class I, and antigen processing via proteolysis, which in turn can be regulated by the kinetics of endosomal maturation and acidification (40) . Specifically, retention of the antigenic material in a less acidic early endosomal-like compartment appears to be critical for efficient antigen cross-presentation. Consistent with this idea, antigens targeted to different endocytosis receptors that vary in their kinetics of lysosomal targeting are cross-presented with different efficiencies (41) . In this context, it is interesting to note that while CD36, αvβ5, and αvβ3 mediate uptake of ACs by human DCs in vitro, they do not play a significant role in antigen cross-presentation in vitro (12, 13) . Thus, the identification of efferocytosis receptors that are efficient at targeting antigens for cross-presentation will likely have important implications for understanding basic DC biology and for therapeutically targeting antigens to optimally activate CD8 + T cells. Our present data showed that the AXL/LRP-1/RANBP9 complex in DCs mediated cross-presentation of AC-derived antigens both in vitro in an OVA-OT-I model as well as in vivo in a natural HSV-1 infection model. Consistent with a previous report, blocking TIM-3 using an anti-TIM-3 nAb resulted in inhibition of both efferocytosis and cross-presentation of AC-associated antigen in vitro (data not shown). However, in view of the key roles of TIM-3 in T cell biology (14) , addressing the role of TIM-3 in crosspresentation in vivo will require the use of a DC-specific TIM-3 deletion model, which has not yet been reported.
The transgenic OT-1 and gBT-I.1 CD8 + T cells featured in the present study are routinely used to assay antigen cross-presentation on MHC class I (32, 42) . While this is a useful system, it is highly sensitive; hence, the data derived from this assay must be interpreted in the context that the T cell subsets being monitored in this model have receptors with single high-affinity antigen specificity. In this context, it is remarkable that even partial inhibition of efferocytosis via blockage of the AXL/LRP-1/ RANBP9 pathway resulted in inhibition of cross-presentation in this highly sensitive assay. It is likely that inhibition of crosspresentation to endogenous T cells, which would presumably not express such high-affinity receptors, would be even higher than that observed with transgenic T cells. In support of this idea, our data demonstrated that blocking AXL/LRP-1/RANBP9-mediated efferocytosis resulted in enhanced HSV-1 pathogenesis, despite only approximately 30% inhibition in proliferation of gBT-I.1 transgenic T cells. Whether additional or alternative mechanisms are involved in this effect will require further study. For example, DNGR-1, a c-type lectin receptor that recognizes F-actin exposed by necrotic cells (43, 44) , has been implicated in mediating crosspresentation and antiviral immunity by retaining the internalized necrotic cargo in an early endosomal compartment that facilitates cross-presentation (45, 46) . trol was injected into mice 30 minutes prior to injection of labeled ACs. 3 hours later, mice were euthanized by CO2 asphyxiation, and splenocytes were harvested by gently disaggregating the spleen tissue in a buffer containing 300 μg/ml collagenase D (Sigma-Aldrich). The splenocytes were stained with fluorophore-conjugated antibodies against CD11c, CD8α, and F4/80 (BD Biosciences) and analyzed by flow cytometry (BD FACS calibur or BD FACS canto II) using FlowJo software (Tree Star Inc.). Cell sorting was conducted at the flow cytometry core facility of Columbia Center for Translational Immunology using a BD influx cell sorter.
FRET assay. Antibodies against AXL and LRP-1 (R&D Systems and Sigma-Aldrich, respectively) were conjugated to Alexa Fluor 546 or Alexa Fluor 647 using a commercially available antibody labeling kit (Invitrogen). The labeling ratio was approximately 3, calculated according to the manufacturer's instructions. Antibody labeling of cells was performed at 4°C for 30 minutes. FRET analysis was conducted by flow cytometry on CD11c higated cells using a BD FACS Calibur equipped with 488-and 635-nm lasers. Data were analyzed using FlowJo software.
IP and Western blotting. IP was performed by lysing in vitro-cultured DCs using an IP buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% Triton X-100, and 1 tablet of Roche EDTAfree protease inhibitor per 10 ml of buffer. Lysates were then incubated with protein A-sepharose beads (GE Healthcare) and 100 μg anti-AXL (Cell Signaling Technology) or anti-LRP-1 (Sigma-Aldrich) antibody overnight at 4°C on a rotor-shaker. Samples were centrifuged at 90 g for 5 minutes, and beads were washed and recentrifuged 3 times with IP buffer. Laemmli buffer was then added to the beads; after boiling, the suspensions were centrifuged at 9,000 g. The supernatant fractions were loaded onto 4%-20% Tris-glycine SDS-PAGE gels. After transfer onto nitrocellulose membranes, blots were probed for AXL (R&D Systems), LRP-1 (Sigma-Aldrich), and RANBP9 (Epitomics) using specific antibodies, and the immunoreactive bands were visualized by enhanced chemiluminescence (Thermo Scientific).
siRNA transfection. BMDCs (5 × 10 5 cells/well of 24-well non-tissue culture-treated plates) were resuspended in serum-free DMEM. siRNA transfection complex was prepared by incubating 20 pmol Gulp1 siRNA (Qiagen) with Lipofectamine 2000 (Invitrogen) (1:1 ratio) in serum-free DMEM for 20 minutes at room temperature. BMDCs were incubated with 20 pmol siRNA transfection complex under serum-free conditions for 6 hours at 37°C in a 5% CO2 incubator, after which the culture medium was supplemented with serum to a final concentration of 5%. Cells were harvested 24 hours after transfection; knockdown efficiency was analyzed by measuring Gulp1 mRNA by RT-qPCR.
Fetal liver transplantation. E15 embryos from pregnant mice of Ranbp9 +/-matings were harvested. Portions of the tail and head were preserved for genotyping by PCR and Western blotting to identify Ranbp9 -/-embryos. Under sterile conditions, the fetal livers were harvested, and cell suspensions were prepared by passing the liver tissue sequentially 3 times through a 20-gauge needle and 1 time through a 25-gauge needle. Cells were centrifuged at 130 g for 5 minutes, resuspended in serum-free DMEM, and counted using a hemocytometer. 2 × 10 6 cells were injected i.v. into lethally irradiated (10 Gy; Gammacell40 unit) C57BL/6J recipient mice. Recipient mice were fed antibiotic water (100 μg/ml neomycin and 10 μg/ml polymyxin B) for 2 weeks and then acidified water. Chimeric mice were used 4 weeks after fetal liver transplantation.
In vitro antigen cross-presentation assay. Jurkat cells were incubated with 1 mg/ml OVA, and the OVA-loaded cells were exposed to UV light to induce apoptosis. BMDCs from appropriate groups of mice were incubated with OVA-loaded ACs for 2 hours to facilitate efferocytosis. FACS-sorted CD8 + T cells from OT-1 transgenic mice, which express TCR specific to OVA257-264, were labeled with 5 μM CFSE as described previously (56) . These CFSElabeled OT-1 T cells (5 × 10 4 /well) were then cultured with BMDCs Primary culture of BMDCs. Murine bone marrow cells were isolated from the femurs of mice, cultured for 7 days in petri dishes in DMEM containing 10% FBS, and supplemented daily with GM-CSF (10 ng/ml) and IL-4 (10 ng/ml). On day 3, half the medium was replaced to replenish nutrients. The nonadherent cells were harvested on day 7, and experiments were performed by plating these cells on non-tissue culture-treated 24-well plates. To delete RANBP9 in BMDCs generated from the bone marrow of Ranbp9 fl/fl mice, cells were transduced with an adenoviral vector encoding Cre or LacZ control at an MOI of 200:1 (virus/DC), and experiments were conducted 48 hours later. Adeno-Cre and adeno-LacZ were obtained from Viraquest.
Generation of human peripheral blood monocyte-derived DCs. Buffy coats were obtained from New York Blood Center. The mononuclear cell layer was isolated by gradient centrifugation using Ficoll-Hypaque, then plated and incubated in tissue culture dishes. After 1 hour, the nonadherent cells were washed away. The medium (DMEM containing 10% FBS) was supplemented with 500 IU recombinant human GM-CSF and IL-4 on days 0 and 3 of culture. The nonadherent cell population on day 7 was used as DCs.
Human splenic DC isolation. Human spleen samples were maintained in cold saline and brought to the laboratory within 6 hours of organ procurement. In order to ensure high live cell yield, samples were rapidly processed through both enzymatic and mechanical digestion methods. Spleen was cleaned of fat, chopped into small pieces, and placed into 50-ml conical tubes. Enzymatic digestion media (25 ml) was added (RPMI containing 10% FBS, l-glutamate, sodium pyruvate, nonessential amino acids, penicillin-streptomycin, 1 mg/ml collagenase D, 1 mg/ml trypsin inhibitor, and 0.1 mg/ml DNase I) and incubated with mechanical shaking at 37°C for 1 hour. Digested tissue was then disrupted using the gentleMACS tissue dissociator (Miltenyi Biotech), and the resulting suspension was passed through a stainless steel tissue sieve (mesh size, 10-150), followed by centrifugation. Red blood cell lysis was performed by addition of 5 ml ACK lysis buffer (Cellgro) directly to the cell pellet and incubation with periodic agitation for 5 minutes. To remove dead cells and debris, cell pellets were resuspended in 20 ml of 30% percoll (GE Healthcare Life Sciences) and centrifuged at 50 g for 12 minutes. The resulting top layer and bottom pellet were discarded. Cells were washed with complete RPMI to remove percoll, and the resulting cell suspension was passed through a 40-μm filter. DCs were obtained from this cell suspension by negative selection using human myeloid DC isolation kit (Miltenyi Biotech).
Generation of fluorescently labeled ACs. Mouse splenocytes (in vivo experiments) or Jurkat cells (in vitro experiments) were labeled with PKH67-GL (2 μM; Sigma-Aldrich) per the manufacturer's instructions. Cells were then exposed to ultraviolet light (254 nm, UVP) for 5 minutes for induction of apoptosis. After UV exposure, cells were incubated in a 37°C incubator with 5% CO2 for 1 hour (Jurkat cells) or 3 hours (splenocytes). We routinely obtained approximately 80% early ACs (annexin V + PI -) at these time points.
In vitro AC binding and engulfment assay. AC binding experiments were conducted on BMDCs (5 × 10 5 cells/well on 24-well non-tissue culturecoated plates). Internalization was blocked either by pretreatment with 5 μg/ml cytochalasin D for 30 minutes, followed by incubation with PKH67-labeled ACs (1:5 BMDC/AC ratio) for 1 hour at 37°C, or by incubation with ACs at 4°C for 1 hour. AC engulfment experiments were conducted by incubating DCs with ACs for 2 hours at 37°C in the absence of cytochalasin D. For quantification, cells were mounted on slides and analyzed by fluorescence microscopy to determine the percentage of DCs labeled with PKH67-tagged ACs.
In vivo splenic DC efferocytosis assay. 2 × 10 7 apoptotic splenocytes were labeled ex vivo with 100 μg/ml PKH67-GL or Cypher-5E (GE Healthcare) per the manufacturer's instructions. The labeled cells were then injected i.v. into mice. For inhibition experiments, GST (2 mg/mouse i.v.), GST-RAP (2 mg/mouse i.v.), TIM-3 nAb (100 μg/mouse i.p.), or appropriate IgG con-Study approval. All animals used in this study were maintained in a barrier facility. All animal protocols were approved by the Columbia University Institutional Animal Care and Use Committee. Human spleens were obtained from deceased organ donors, at the time of organ acquisition for transplantation, through an approved research protocol and MTA with the New York Organ Donor Network (NYODN). All donors were 73 years or younger, were free of chronic disease and cancer, and were negative for hepatitis B and C and for HIV. Because tissue samples were obtained from deceased individuals lacking identifiers for our experiments, this study did not qualify as human subjects research, as confirmed by the Columbia University Institutional Review Board. Research consent for the donor tissue was obtained by the NYODN transplant coordinators.
